{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-220529","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2024-09-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.006444+00:00","generated_at":"2026-05-31T04:13:51.827482+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Kura Oncology appoints Michael Vasconcelles, M.D. to board and compensation committee","bullets":["Appointed as Class III director with term expiring at 2026 annual meeting.","Annual cash retainer $40,000 for board service plus $7,500 for Compensation Committee.","Granted option to purchase 52,000 shares (3-year vest) and 17,333 shares (1-year cliff).","Eligible for future automatic annual option grants of 26,000 shares.","Standard indemnification agreement; no reportable transactions under Item 404."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-220529","json":"https://secwatch.observer/filing/0001193125-24-220529.json","markdown":"https://secwatch.observer/filing/0001193125-24-220529.md","text":"https://secwatch.observer/filing/0001193125-24-220529.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000119312524220529/0001193125-24-220529-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000119312524220529/d866748d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:13:51.827482+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"045d273e6f","claim":"Michael J. Vasconcelles, M.D. was appointed as Class III Director at Kura Oncology, Inc..","evidence_excerpt":"On September 13, 2024, the Board of Directors (the “Board”) of Kura Oncology, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Michael J. Vasconcelles, M.D. as (i) a Class III director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312524220529/0001193125-24-220529-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}